FDA Advisory Panel to Re-Evaluate Popular Osteoporosis Drugs

by Kathy Jones on  September 8, 2011 at 5:35 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Popular osteoporosis drugs known as bisphosphonates are being re-evaluated by the advisory panel of the US Food and Drug Administration after recent studies linked this class of drugs with brittle bones in thighs and the jaw.
 FDA Advisory Panel to Re-Evaluate Popular Osteoporosis Drugs
FDA Advisory Panel to Re-Evaluate Popular Osteoporosis Drugs

A study conducted by the American Society of Bone and Mineral Research last September revealed that bisphosphonates increased the risk of rare femur fracture among patients suffering from osteoporosis. The researchers observed 310 cases of such fractures and found that more than 94 percent of them had taken the drugs.

The researchers suggested that the FDA should consider their study and change the drugs' labeling to display warnings of such risks.

One of the popular bisphosphonate drugs, Fosamax, has also been linked with osteonecrosis of the jaw, though its manufacturer Merck said that the studies lack any clinical evidence.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Fracture Rickets Osteoporosis Lifestyle And Osteoporosis Kyphosis Colle’s Fracture Fracture Neck of Femur Back Pain at Workplace: Prevention and Exercises Screening for Osteoporosis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive